An Study to Compare Single-dose Pharmacokinetic and Pharmacodynamic Characteristics of Epogen® and Epoetin Alfas (Eprex® and Binocrit®) in Healthy Subjects.

Trial Identifier: D5740C00003
Sponsor: AstraZeneca
Start Date: June 2018
Primary Completion Date: November 2018
Condition: Anemia; Chronic Kidney Diseases

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description
English Translation
German Translation

Trial Locations

Country Location
Germany Berlin, Germany, 14050